We collect cookies for vital website function and to better serve our customers. By continuing to browse you agree to the storing of cookies on your device. See our privacy policy for details.

Bortezomib

Item № 10008822
CAS № 179324-69-7
Purity ≥95%
product image
                (CAS 179324-69-7)
SIZE PRICE QUANTITY SUBTOTAL
CART TOTAL
     1 mg $25.00 0.00
     5 mg $56.00 0.00
     10 mg $100.00 0.00
     25 mg $219.00 0.00

Pricing updated 2019-03-24. Prices are subject to change without notice.

Description
Synonyms
  • LDP-341
  • MG-341
  • MLN341
  • NSC 681239
  • PS-341
  • Velcade

Bortezomib is a dipeptide boronic acid derivative that reversibly inhibits the 20S proteasome (Ki = 0.6 nM).1 It binds the β5-subunit of the 20S proteasome and selectively inhibits chymotryptic activity.2,3,4 In part by blocking the degradation of tumor-suppressing and proapoptotic proteins, bortezomib drives cell cycle arrest and apoptosis in cancer cell lines and has applications in multiple myeloma and certain lymphomas, as well as other types of cancer.1,5 Proteasome inhibitors, including bortezomib, have potential in combination therapy with chemotherapy and radiation therapy against cancer.6,7,8,9

Recommended Products

Related Products
View Related Product Categories
Technical Information
Formal Name
B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-boronic acid
CAS Number
179324-69-7
Synonyms
  • LDP-341
  • MG-341
  • MLN341
  • NSC 681239
  • PS-341
  • Velcade
Molecular Formula
C19H25BN4O4
Formula Weight
384.2
Purity
≥95%
Formulation
A crystalline solid
λmax
269 nm
SMILES
O=C(N[C@@H](CC1=CC=CC=C1)C(N[C@H](B(O)O)CC(C)C)=O)C2=CN=CC=N2
InChI Code
InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1
InChI Key
GXJABQQUPOEUTA-RDJZCZTQSA-N

Warning - this product is not for human or veterinary use.

Shipping & Storage
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Stability
≥ 2 years
Downloads & Resources
Product Downloads

Download Product Insert

Download Safety Data Sheet (SDS)

Download free InChI Key generation software

Additional Information

View the Cayman Structure Database for chemical structure definitions for many Cayman products

Get Batch-Specific Data and Documents by Batch Number

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data pack, and GC-MS data.

References & Product Citations
Product Description References

1. Ludwig, H., Khayat, D., Giaccone, G., et al. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies Cancer 104, 1794-1807 (2005).

2. Lightcap, E.S., McCormack, T.A., Pien, C.S., et al. Proteasome inhibition measurements: Clinical application Clinical Chemistry 46(5), 673-683 (2000).

3. Adams, J. Development of the proteasome inhibitor PS-341 The Oncologist 7, 9-16 (2002).

4. Dou, Q.P., and Zonder, J.A. Overview of proteasome inhibitor-based anti-cancer therapies: Perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system Curr. Cancer Drug Targets 14(6), 517-536 (2014).

5. Richardson, P.G., Hideshima, T., and Anderson, K.C. Bortezomib (PS-341): A novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers Cancer Control 10(5), 361-369 (2003).

6. Mandl-Weber, S., Meinel, F.G., Jankowsky, R., et al. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells British Journal of Haematology 149, 518-528 (2010).

7. Minami, J., Suzuki, R., Mazitschek, R., et al. Histone deacetylase 3 (HDAC3) as a novel therapeutic target in multiple myeloma Leukemia 28(3), 680-689 (2014).

8. Mato, A.R., Feldman, T., and Goy, A. Proteasome inhibition and combination therapy for non-Hodgkin’s lymphoma: From bench to bedside Oncologist 17(5), 694-707 (2012).

9. Al-Eisawi, Z., Beale, P., Chan, C., et al. Carboplatin and oxaliplatin in sequenced combination with bortezomib in ovarian tumour models J.Ovarian Res. 6(1), 78 (2013).

Technical Support
Contact Us
  • Toll Free Phone (USA and Canada Only): (888) 526-5351
  • Direct Phone: (734) 975-3888
Cayman Contract Services

We work with scientists to accelerate their research, drug discovery, and drug development needs through our expertise in the following areas:

Cayman Chemical

1180 East Ellsworth Road

Ann Arbor, Michigan 48108 USA

Toll Free: (800) 364-9897

(USA and Canada Only)

Fax: (734) 971-3640